Early intervention of atopic dermatitis as a preventive strategy for progression of food allergy
Background Atopic diseases, such as atopic dermatitis (AD) and food allergy (FA), have increased in prevalence in industrialized countries during the past few decades and pose a significant health burden. They appear to have a common underlying mechanism and a natural disease progression. AD is gene...
Uložené v:
| Vydané v: | Allergy, asthma, and clinical immunology Ročník 17; číslo 1; s. 30 - 12 |
|---|---|
| Hlavní autori: | , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
London
BioMed Central
16.03.2021
BioMed Central Ltd BMC |
| Predmet: | |
| ISSN: | 1710-1492, 1710-1484, 1710-1492 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Background
Atopic diseases, such as atopic dermatitis (AD) and food allergy (FA), have increased in prevalence in industrialized countries during the past few decades and pose a significant health burden. They appear to have a common underlying mechanism and a natural disease progression. AD is generally the first atopic disease to manifest followed by other atopic diseases, such as FA, allergic rhinitis, or allergic asthma suggesting that they are likely different manifestations of the same disease.
Body
Evidence suggests that allergic sensitization occurs through an impaired skin barrier, while consumption of these foods at an early age may actually result in tolerance. This has been termed the Dual-Allergen-Exposure hypothesis. Loss of barrier integrity has been hypothesized to enable penetration of allergens, pollutants, and microbes and initiation of an inflammatory immune cascade of events leading to sensitization. The immune dysfunction is thought to further exacerbate the impaired skin barrier to form a vicious cycle. There is much interest in preventing or protecting the skin barrier from developing a proinflammatory atopic state, which may potentially lead to the development of AD and subsequently, FA.
Conclusion
Research on preventing or treating skin barrier dysfunction is ongoing. A number of studies have evaluated the efficacy of emollients in preventing AD and FA with mixed results. Studies have differed in the study design, population characteristics, emollients type, and frequency, duration, and area of application. Emollient type has varied widely from oils, creams, petrolatum-based lotions, and trilipid creams. Current research is directed towards the use of trilipid emollients that are similar to the skin’s natural lipid composition with a 3:1:1 ratio of ceramides, cholesterol and free fatty acids and a pH that is similar to that of skin to determine their effectiveness for skin barrier repair and prevention of AD and FA. |
|---|---|
| AbstractList | Atopic diseases, such as atopic dermatitis (AD) and food allergy (FA), have increased in prevalence in industrialized countries during the past few decades and pose a significant health burden. They appear to have a common underlying mechanism and a natural disease progression. AD is generally the first atopic disease to manifest followed by other atopic diseases, such as FA, allergic rhinitis, or allergic asthma suggesting that they are likely different manifestations of the same disease. BODY: Evidence suggests that allergic sensitization occurs through an impaired skin barrier, while consumption of these foods at an early age may actually result in tolerance. This has been termed the Dual-Allergen-Exposure hypothesis. Loss of barrier integrity has been hypothesized to enable penetration of allergens, pollutants, and microbes and initiation of an inflammatory immune cascade of events leading to sensitization. The immune dysfunction is thought to further exacerbate the impaired skin barrier to form a vicious cycle. There is much interest in preventing or protecting the skin barrier from developing a proinflammatory atopic state, which may potentially lead to the development of AD and subsequently, FA.BACKGROUNDAtopic diseases, such as atopic dermatitis (AD) and food allergy (FA), have increased in prevalence in industrialized countries during the past few decades and pose a significant health burden. They appear to have a common underlying mechanism and a natural disease progression. AD is generally the first atopic disease to manifest followed by other atopic diseases, such as FA, allergic rhinitis, or allergic asthma suggesting that they are likely different manifestations of the same disease. BODY: Evidence suggests that allergic sensitization occurs through an impaired skin barrier, while consumption of these foods at an early age may actually result in tolerance. This has been termed the Dual-Allergen-Exposure hypothesis. Loss of barrier integrity has been hypothesized to enable penetration of allergens, pollutants, and microbes and initiation of an inflammatory immune cascade of events leading to sensitization. The immune dysfunction is thought to further exacerbate the impaired skin barrier to form a vicious cycle. There is much interest in preventing or protecting the skin barrier from developing a proinflammatory atopic state, which may potentially lead to the development of AD and subsequently, FA.Research on preventing or treating skin barrier dysfunction is ongoing. A number of studies have evaluated the efficacy of emollients in preventing AD and FA with mixed results. Studies have differed in the study design, population characteristics, emollients type, and frequency, duration, and area of application. Emollient type has varied widely from oils, creams, petrolatum-based lotions, and trilipid creams. Current research is directed towards the use of trilipid emollients that are similar to the skin's natural lipid composition with a 3:1:1 ratio of ceramides, cholesterol and free fatty acids and a pH that is similar to that of skin to determine their effectiveness for skin barrier repair and prevention of AD and FA.CONCLUSIONResearch on preventing or treating skin barrier dysfunction is ongoing. A number of studies have evaluated the efficacy of emollients in preventing AD and FA with mixed results. Studies have differed in the study design, population characteristics, emollients type, and frequency, duration, and area of application. Emollient type has varied widely from oils, creams, petrolatum-based lotions, and trilipid creams. Current research is directed towards the use of trilipid emollients that are similar to the skin's natural lipid composition with a 3:1:1 ratio of ceramides, cholesterol and free fatty acids and a pH that is similar to that of skin to determine their effectiveness for skin barrier repair and prevention of AD and FA. Background Atopic diseases, such as atopic dermatitis (AD) and food allergy (FA), have increased in prevalence in industrialized countries during the past few decades and pose a significant health burden. They appear to have a common underlying mechanism and a natural disease progression. AD is generally the first atopic disease to manifest followed by other atopic diseases, such as FA, allergic rhinitis, or allergic asthma suggesting that they are likely different manifestations of the same disease. Body Evidence suggests that allergic sensitization occurs through an impaired skin barrier, while consumption of these foods at an early age may actually result in tolerance. This has been termed the Dual-Allergen-Exposure hypothesis. Loss of barrier integrity has been hypothesized to enable penetration of allergens, pollutants, and microbes and initiation of an inflammatory immune cascade of events leading to sensitization. The immune dysfunction is thought to further exacerbate the impaired skin barrier to form a vicious cycle. There is much interest in preventing or protecting the skin barrier from developing a proinflammatory atopic state, which may potentially lead to the development of AD and subsequently, FA. Conclusion Research on preventing or treating skin barrier dysfunction is ongoing. A number of studies have evaluated the efficacy of emollients in preventing AD and FA with mixed results. Studies have differed in the study design, population characteristics, emollients type, and frequency, duration, and area of application. Emollient type has varied widely from oils, creams, petrolatum-based lotions, and trilipid creams. Current research is directed towards the use of trilipid emollients that are similar to the skin's natural lipid composition with a 3:1:1 ratio of ceramides, cholesterol and free fatty acids and a pH that is similar to that of skin to determine their effectiveness for skin barrier repair and prevention of AD and FA. Keywords: Atopic dermatitis, Ceramides, Eczema, Emollients, Filaggrin, Food allergy, Prevention, Skin barrier, Stratum corneum, Trilipids Abstract Background Atopic diseases, such as atopic dermatitis (AD) and food allergy (FA), have increased in prevalence in industrialized countries during the past few decades and pose a significant health burden. They appear to have a common underlying mechanism and a natural disease progression. AD is generally the first atopic disease to manifest followed by other atopic diseases, such as FA, allergic rhinitis, or allergic asthma suggesting that they are likely different manifestations of the same disease. Body Evidence suggests that allergic sensitization occurs through an impaired skin barrier, while consumption of these foods at an early age may actually result in tolerance. This has been termed the Dual-Allergen-Exposure hypothesis. Loss of barrier integrity has been hypothesized to enable penetration of allergens, pollutants, and microbes and initiation of an inflammatory immune cascade of events leading to sensitization. The immune dysfunction is thought to further exacerbate the impaired skin barrier to form a vicious cycle. There is much interest in preventing or protecting the skin barrier from developing a proinflammatory atopic state, which may potentially lead to the development of AD and subsequently, FA. Conclusion Research on preventing or treating skin barrier dysfunction is ongoing. A number of studies have evaluated the efficacy of emollients in preventing AD and FA with mixed results. Studies have differed in the study design, population characteristics, emollients type, and frequency, duration, and area of application. Emollient type has varied widely from oils, creams, petrolatum-based lotions, and trilipid creams. Current research is directed towards the use of trilipid emollients that are similar to the skin’s natural lipid composition with a 3:1:1 ratio of ceramides, cholesterol and free fatty acids and a pH that is similar to that of skin to determine their effectiveness for skin barrier repair and prevention of AD and FA. Atopic diseases, such as atopic dermatitis (AD) and food allergy (FA), have increased in prevalence in industrialized countries during the past few decades and pose a significant health burden. They appear to have a common underlying mechanism and a natural disease progression. AD is generally the first atopic disease to manifest followed by other atopic diseases, such as FA, allergic rhinitis, or allergic asthma suggesting that they are likely different manifestations of the same disease. BODY: Evidence suggests that allergic sensitization occurs through an impaired skin barrier, while consumption of these foods at an early age may actually result in tolerance. This has been termed the Dual-Allergen-Exposure hypothesis. Loss of barrier integrity has been hypothesized to enable penetration of allergens, pollutants, and microbes and initiation of an inflammatory immune cascade of events leading to sensitization. The immune dysfunction is thought to further exacerbate the impaired skin barrier to form a vicious cycle. There is much interest in preventing or protecting the skin barrier from developing a proinflammatory atopic state, which may potentially lead to the development of AD and subsequently, FA. Research on preventing or treating skin barrier dysfunction is ongoing. A number of studies have evaluated the efficacy of emollients in preventing AD and FA with mixed results. Studies have differed in the study design, population characteristics, emollients type, and frequency, duration, and area of application. Emollient type has varied widely from oils, creams, petrolatum-based lotions, and trilipid creams. Current research is directed towards the use of trilipid emollients that are similar to the skin's natural lipid composition with a 3:1:1 ratio of ceramides, cholesterol and free fatty acids and a pH that is similar to that of skin to determine their effectiveness for skin barrier repair and prevention of AD and FA. Atopic diseases, such as atopic dermatitis (AD) and food allergy (FA), have increased in prevalence in industrialized countries during the past few decades and pose a significant health burden. They appear to have a common underlying mechanism and a natural disease progression. AD is generally the first atopic disease to manifest followed by other atopic diseases, such as FA, allergic rhinitis, or allergic asthma suggesting that they are likely different manifestations of the same disease. Background Atopic diseases, such as atopic dermatitis (AD) and food allergy (FA), have increased in prevalence in industrialized countries during the past few decades and pose a significant health burden. They appear to have a common underlying mechanism and a natural disease progression. AD is generally the first atopic disease to manifest followed by other atopic diseases, such as FA, allergic rhinitis, or allergic asthma suggesting that they are likely different manifestations of the same disease. Body Evidence suggests that allergic sensitization occurs through an impaired skin barrier, while consumption of these foods at an early age may actually result in tolerance. This has been termed the Dual-Allergen-Exposure hypothesis. Loss of barrier integrity has been hypothesized to enable penetration of allergens, pollutants, and microbes and initiation of an inflammatory immune cascade of events leading to sensitization. The immune dysfunction is thought to further exacerbate the impaired skin barrier to form a vicious cycle. There is much interest in preventing or protecting the skin barrier from developing a proinflammatory atopic state, which may potentially lead to the development of AD and subsequently, FA. Conclusion Research on preventing or treating skin barrier dysfunction is ongoing. A number of studies have evaluated the efficacy of emollients in preventing AD and FA with mixed results. Studies have differed in the study design, population characteristics, emollients type, and frequency, duration, and area of application. Emollient type has varied widely from oils, creams, petrolatum-based lotions, and trilipid creams. Current research is directed towards the use of trilipid emollients that are similar to the skin’s natural lipid composition with a 3:1:1 ratio of ceramides, cholesterol and free fatty acids and a pH that is similar to that of skin to determine their effectiveness for skin barrier repair and prevention of AD and FA. Background Atopic diseases, such as atopic dermatitis (AD) and food allergy (FA), have increased in prevalence in industrialized countries during the past few decades and pose a significant health burden. They appear to have a common underlying mechanism and a natural disease progression. AD is generally the first atopic disease to manifest followed by other atopic diseases, such as FA, allergic rhinitis, or allergic asthma suggesting that they are likely different manifestations of the same disease. Body Evidence suggests that allergic sensitization occurs through an impaired skin barrier, while consumption of these foods at an early age may actually result in tolerance. This has been termed the Dual-Allergen-Exposure hypothesis. Loss of barrier integrity has been hypothesized to enable penetration of allergens, pollutants, and microbes and initiation of an inflammatory immune cascade of events leading to sensitization. The immune dysfunction is thought to further exacerbate the impaired skin barrier to form a vicious cycle. There is much interest in preventing or protecting the skin barrier from developing a proinflammatory atopic state, which may potentially lead to the development of AD and subsequently, FA. Conclusion Research on preventing or treating skin barrier dysfunction is ongoing. A number of studies have evaluated the efficacy of emollients in preventing AD and FA with mixed results. Studies have differed in the study design, population characteristics, emollients type, and frequency, duration, and area of application. Emollient type has varied widely from oils, creams, petrolatum-based lotions, and trilipid creams. Current research is directed towards the use of trilipid emollients that are similar to the skin’s natural lipid composition with a 3:1:1 ratio of ceramides, cholesterol and free fatty acids and a pH that is similar to that of skin to determine their effectiveness for skin barrier repair and prevention of AD and FA. |
| ArticleNumber | 30 |
| Audience | Academic |
| Author | Sweeney, Alyssa Sampath, Vanitha Nadeau, Kari C. |
| Author_xml | – sequence: 1 givenname: Alyssa surname: Sweeney fullname: Sweeney, Alyssa organization: Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Stanford University – sequence: 2 givenname: Vanitha surname: Sampath fullname: Sampath, Vanitha organization: Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Stanford University – sequence: 3 givenname: Kari C. orcidid: 0000-0002-2146-2955 surname: Nadeau fullname: Nadeau, Kari C. email: knadeau@stanford.edu organization: Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Stanford University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33726824$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kl1r2zAUhs3oWD-2P7CLYRiM3biTjvwh3QxK6dZCYTfbtSbLR46CY2WSEsi_r5ykbVJGscDm6H2f43N4z7OT0Y2YZR8puaSU198CZQCsIEALQipGC_4mO6MNJQUtBZwcfJ9m5yHMCSkpZ_AuO2WsgZpDeZb9vVF-2OR2jOjXOEbrxtyZXEW3tDrv0C9UtNGGXKWTLz1uRWvMQ_QqYr_JjfOp7nqPIezdxrkuV8OAvt-8z94aNQT8sH9fZH9-3Py-vi3uf_28u766L3TNeCw6RjgVYFAAEKSMI3JSpRpWlArBjOaMKNWAAQLClGXbcWwbrTU2ytSKXWR3O27n1FwuvV0ov5FOWbktON9L5aPVA0oQLevqtuINE6Xp2pbrWhCAFgVyVBPr-461XLUL7HQa2avhCHp8M9qZ7N1aNqIGxngCfN0DvPu3whDlwgaNw6BGdKsgoUrt0lwVJOnnF9K5W_kxrWqrEsBrIM-qXqUB7Ghc6qsnqLyqq7qkjPKp7eV_VOnpcGF1Co-xqX5k-HJgmKEa4iy4YTXFIBwLPx1u5GkVj0FKAr4TaO9C8GiktlFNnPQLdpCUyCmzcpdZmTIrt5mVExteWB_pr5rYzhSSeOzRP6_tFdcDrS38-g |
| CitedBy_id | crossref_primary_10_1007_s12016_023_08977_x crossref_primary_10_1016_j_jaci_2021_10_018 crossref_primary_10_1016_j_jaci_2022_12_819 crossref_primary_10_4103_ijd_ijd_989_21 crossref_primary_10_2196_72925 crossref_primary_10_1007_s40267_022_00977_9 crossref_primary_10_3390_jpm12060893 crossref_primary_10_1007_s11882_022_01061_y crossref_primary_10_3389_fimmu_2022_949665 crossref_primary_10_1055_a_2538_5769 crossref_primary_10_3390_children10010088 crossref_primary_10_1186_s13223_024_00894_8 crossref_primary_10_1002_clt2_12270 crossref_primary_10_1007_s12016_025_09075_w crossref_primary_10_1016_j_anai_2022_06_030 crossref_primary_10_3389_fsci_2024_1279192 crossref_primary_10_1016_j_bcp_2025_116879 crossref_primary_10_3390_nu17162582 crossref_primary_10_3390_nu14061317 |
| Cites_doi | 10.1159/000497382 10.1016/j.jaci.2015.12.1312 10.1111/cea.12406 10.1016/j.anai.2017.11.023 10.1016/j.jaci.2014.08.011 10.1056/NEJMoa1414850 10.1056/NEJMra1011040 10.1111/jdv.15786 10.1038/jid.2009.133 10.1016/j.jaci.2017.11.003 10.1007/s11882-020-0898-7 10.1016/j.jaci.2014.07.060 10.1016/j.jaip.2017.10.024 10.1016/j.jaci.2014.10.007 10.1111/1523-1747.ep12340135 10.1159/000501636 10.1159/000094670 10.1016/j.anai.2017.10.037 10.1016/j.jaci.2013.02.034 10.1016/j.det.2017.02.002 10.1186/s12940-020-0563-6 10.1542/peds.111.S3.1662 10.1016/j.jaci.2014.12.013 10.1001/jamapediatrics.2013.2376 10.1016/j.jaci.2010.10.007 10.3345/kjp.2017.60.5.145 10.1172/JCI1647 10.1111/pai.12908 10.1111/bjd.16934 10.1016/j.jaci.2019.06.045 10.1067/mpd.2000.109376 10.1111/all.12268 10.1001/archderm.131.7.809 10.1016/j.coi.2020.02.007 10.1016/S0140-6736(19)32984-8 10.1016/j.immuni.2015.07.007 10.4168/aair.2020.12.1.137 10.1016/j.dsi.2015.03.010 10.1067/mai.2001.112129 10.1111/1346-8138.14080 10.1056/NEJMoa013536 10.1007/978-981-15-3449-2_4 10.1056/NEJMoa1514210 10.1016/j.jaci.2014.08.005 10.1016/S0140-6736(19)32983-6 10.1080/1744666X.2019.1641406 10.1038/s41572-018-0001-z 10.1016/j.envres.2017.10.030 10.1001/jamapediatrics.2018.0315 10.23736/S0392-0488.19.06430-7 10.1016/j.jaip.2018.10.043 10.1016/j.jaip.2012.11.005 10.1016/j.jaci.2019.09.004 10.1007/s00394-018-1703-4 10.1111/pai.13314 10.1016/j.anai.2018.06.008 10.1111/j.1365-2133.2010.10068.x 10.1159/000500402 10.1111/bjd.15747 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2021 COPYRIGHT 2021 BioMed Central Ltd. 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2021 – notice: COPYRIGHT 2021 BioMed Central Ltd. – notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION NPM 3V. 7X7 7XB 88C 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M0T PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s13223-021-00531-8 |
| DatabaseName | Springer Nature OA Free Journals CrossRef PubMed ProQuest Central (Corporate) ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Healthcare Administration Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic Eastern Edition ProQuest Health Management ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Open Access Full Text url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: ProQuest Publicly Available Content url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1710-1492 |
| EndPage | 12 |
| ExternalDocumentID | oai_doaj_org_article_29b3d6b587394fdbb8c69022be9e8eaa PMC7962338 A656413188 33726824 10_1186_s13223_021_00531_8 |
| Genre | Journal Article Review |
| GeographicLocations | United States--US |
| GeographicLocations_xml | – name: United States--US |
| GrantInformation_xml | – fundername: Sean N. Parker Center for Allergy and Asthma Research at Stanford University – fundername: ; |
| GroupedDBID | --- 4.4 53G 5GY 5VS 6J9 7X7 8FI 8FJ AAFWJ AAJSJ AASML ABDBF ABUWG ACGFS ACIHN ACUHS ADBBV ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS AQUVI BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IEA IHR IHW INH INR ITC KQ8 M0T M48 O5R O5S OK1 P6G PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PUEGO RBZ RNS ROL RPM RSV SMD SOJ TR2 TUS UKHRP AAYXX AFFHD CITATION ALIPV NPM 3V. 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c638t-d308192fe9220e138ee805081e511993fc830aa72f2029f44bd8eb7ccce7af6a3 |
| IEDL.DBID | BENPR |
| ISICitedReferencesCount | 27 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000629581000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1710-1492 1710-1484 |
| IngestDate | Mon Nov 10 04:35:16 EST 2025 Tue Nov 04 01:55:40 EST 2025 Thu Sep 04 19:50:33 EDT 2025 Sat Nov 29 14:50:42 EST 2025 Tue Nov 11 10:04:52 EST 2025 Tue Nov 04 17:53:07 EST 2025 Thu May 22 21:23:25 EDT 2025 Thu Apr 03 07:07:37 EDT 2025 Sat Nov 29 03:55:01 EST 2025 Tue Nov 18 22:11:50 EST 2025 Sat Sep 06 07:30:59 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Prevention Trilipids Food allergy Stratum corneum Skin barrier Atopic dermatitis Eczema Ceramides Filaggrin Emollients |
| Language | English |
| License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c638t-d308192fe9220e138ee805081e511993fc830aa72f2029f44bd8eb7ccce7af6a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-2146-2955 |
| OpenAccessLink | https://www.proquest.com/docview/2502928620?pq-origsite=%requestingapplication% |
| PMID | 33726824 |
| PQID | 2502928620 |
| PQPubID | 2040175 |
| PageCount | 12 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_29b3d6b587394fdbb8c69022be9e8eaa pubmedcentral_primary_oai_pubmedcentral_nih_gov_7962338 proquest_miscellaneous_2502211952 proquest_journals_2502928620 gale_infotracmisc_A656413188 gale_infotracacademiconefile_A656413188 gale_healthsolutions_A656413188 pubmed_primary_33726824 crossref_citationtrail_10_1186_s13223_021_00531_8 crossref_primary_10_1186_s13223_021_00531_8 springer_journals_10_1186_s13223_021_00531_8 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-03-16 |
| PublicationDateYYYYMMDD | 2021-03-16 |
| PublicationDate_xml | – month: 03 year: 2021 text: 2021-03-16 day: 16 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Allergy, asthma, and clinical immunology |
| PublicationTitleAbbrev | Allergy Asthma Clin Immunol |
| PublicationTitleAlternate | Allergy Asthma Clin Immunol |
| PublicationYear | 2021 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | SH Sicherer (531_CR17) 2018; 141 C Venter (531_CR8) 2019; 7 T Tsakok (531_CR15) 2019; 180 HJ Kim (531_CR37) 2020; 12 TK Vander Leek (531_CR41) 2000; 137 531_CR32 R Gupta (531_CR11) 2013; 167 RS Gupta (531_CR5) 2018; 144 HS Skolnick (531_CR9) 2001; 107 G Man (531_CR58) 2015; 33 JI Silverberg (531_CR1) 2017; 35 HA Brough (531_CR22) 2013; 132 HR Fisher (531_CR48) 2018; 121 AD Irvine (531_CR28) 2011; 365 JM Spergel (531_CR19) 1998; 101 JR Chalmers (531_CR55) 2020; 395 DA Hill (531_CR12) 2018; 120 531_CR25 S Benor (531_CR20) 2019; 179 K Yonezawa (531_CR60) 2018; 45 D McClanahan (531_CR53) 2019; 33 MH Schmid-Wendtner (531_CR35) 2006; 19 EL Simpson (531_CR50) 2014; 134 K Horimukai (531_CR51) 2014; 134 MR Perkin (531_CR46) 2019; 144 AM Drucker (531_CR2) 2018; 6 MM Man (531_CR57) 1996; 106 MM Kelleher (531_CR21) 2016; 137 C Flohr (531_CR29) 2010; 163 E Dissanayake (531_CR54) 2019; 180 SC Dharmage (531_CR18) 2014; 69 HA Brough (531_CR24) 2015; 135 S Weidinger (531_CR27) 2018; 4 CM Warren (531_CR4) 2020; 20 E Mitre (531_CR38) 2018; 172 MR Perkin (531_CR44) 2016; 374 LA Scott (531_CR10) 2019; 15 531_CR59 Z Mu (531_CR30) 2020; 1253 MJ Cork (531_CR36) 2009; 129 MS Motosue (531_CR6) 2018; 29 MM Bergmann (531_CR7) 2013; 1 K Ahn (531_CR40) 2020; 66 G Du Toit (531_CR43) 2015; 372 AJ Lowe (531_CR14) 2018; 120 H Hammad (531_CR16) 2015; 43 HO Skjerven (531_CR56) 2020; 395 MH Mohajeri (531_CR31) 2018; 57 AJ Lowe (531_CR52) 2018; 178 RS Zeiger (531_CR42) 2003; 111 PE Martin (531_CR13) 2015; 45 531_CR45 I Oh (531_CR33) 2018; 160 M Kelleher (531_CR49) 2015; 135 M Loset (531_CR26) 2019; 235 P Voorheis (531_CR47) 2019; 144 P Sciattella (531_CR3) 2020; 155 HA Brough (531_CR23) 2014; 134 SH Lee (531_CR39) 2017; 60 KD Min (531_CR34) 2020; 19 |
| References_xml | – volume: 179 start-page: 187 year: 2019 ident: 531_CR20 publication-title: Int Arch Allergy Immunol doi: 10.1159/000497382 – volume: 137 start-page: 1111 year: 2016 ident: 531_CR21 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2015.12.1312 – volume: 45 start-page: 255 year: 2015 ident: 531_CR13 publication-title: Clin Exp Allergy doi: 10.1111/cea.12406 – volume: 120 start-page: 145 year: 2018 ident: 531_CR14 publication-title: Ann Allergy Asthma Immunol doi: 10.1016/j.anai.2017.11.023 – volume: 134 start-page: 867 year: 2014 ident: 531_CR23 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2014.08.011 – volume: 372 start-page: 803 year: 2015 ident: 531_CR43 publication-title: N Engl J Med doi: 10.1056/NEJMoa1414850 – volume: 144 start-page: S28 year: 2018 ident: 531_CR5 publication-title: Pediatrics – volume: 365 start-page: 1315 year: 2011 ident: 531_CR28 publication-title: N Engl J Med doi: 10.1056/NEJMra1011040 – volume: 33 start-page: 2087 year: 2019 ident: 531_CR53 publication-title: J Eur Acad Dermatol Venereol doi: 10.1111/jdv.15786 – volume: 129 start-page: 1892 year: 2009 ident: 531_CR36 publication-title: J Invest Dermatol doi: 10.1038/jid.2009.133 – volume: 141 start-page: 41 year: 2018 ident: 531_CR17 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2017.11.003 – volume: 20 start-page: 6 year: 2020 ident: 531_CR4 publication-title: Curr Allergy Asthma Rep doi: 10.1007/s11882-020-0898-7 – volume: 134 start-page: 824 year: 2014 ident: 531_CR51 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2014.07.060 – volume: 6 start-page: 1342 year: 2018 ident: 531_CR2 publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2017.10.024 – volume: 135 start-page: 164 year: 2015 ident: 531_CR24 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2014.10.007 – volume: 106 start-page: 1096 year: 1996 ident: 531_CR57 publication-title: J Invest Dermatol doi: 10.1111/1523-1747.ep12340135 – volume: 180 start-page: 202 year: 2019 ident: 531_CR54 publication-title: Int Arch Allergy Immunol doi: 10.1159/000501636 – volume: 19 start-page: 296 year: 2006 ident: 531_CR35 publication-title: Skin Pharmacol Physiol doi: 10.1159/000094670 – volume: 120 start-page: 131 year: 2018 ident: 531_CR12 publication-title: Ann Allergy Asthma Immunol doi: 10.1016/j.anai.2017.10.037 – volume: 132 start-page: 630 year: 2013 ident: 531_CR22 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2013.02.034 – volume: 35 start-page: 283 year: 2017 ident: 531_CR1 publication-title: Dermatol Clin doi: 10.1016/j.det.2017.02.002 – volume: 19 start-page: 6 year: 2020 ident: 531_CR34 publication-title: Environ Health doi: 10.1186/s12940-020-0563-6 – volume: 111 start-page: 1662 year: 2003 ident: 531_CR42 publication-title: Pediatrics doi: 10.1542/peds.111.S3.1662 – volume: 135 start-page: 930 year: 2015 ident: 531_CR49 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2014.12.013 – volume: 167 start-page: 1026 year: 2013 ident: 531_CR11 publication-title: JAMA Pediatr doi: 10.1001/jamapediatrics.2013.2376 – ident: 531_CR45 doi: 10.1016/j.jaci.2010.10.007 – volume: 60 start-page: 145 year: 2017 ident: 531_CR39 publication-title: Korean J Pediatr doi: 10.3345/kjp.2017.60.5.145 – volume: 101 start-page: 1614 year: 1998 ident: 531_CR19 publication-title: J Clin Invest doi: 10.1172/JCI1647 – volume: 29 start-page: 538 year: 2018 ident: 531_CR6 publication-title: Pediatr Allergy Immunol doi: 10.1111/pai.12908 – volume: 180 start-page: 464 year: 2019 ident: 531_CR15 publication-title: Br J Dermatol doi: 10.1111/bjd.16934 – volume: 144 start-page: 1606 year: 2019 ident: 531_CR46 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2019.06.045 – volume: 137 start-page: 749 year: 2000 ident: 531_CR41 publication-title: J Pediatr doi: 10.1067/mpd.2000.109376 – volume: 69 start-page: 17 year: 2014 ident: 531_CR18 publication-title: Allergy doi: 10.1111/all.12268 – ident: 531_CR59 doi: 10.1001/archderm.131.7.809 – volume: 66 start-page: 14 year: 2020 ident: 531_CR40 publication-title: Curr Opin Immunol doi: 10.1016/j.coi.2020.02.007 – volume: 395 start-page: 962 year: 2020 ident: 531_CR55 publication-title: Lancet doi: 10.1016/S0140-6736(19)32984-8 – volume: 43 start-page: 29 year: 2015 ident: 531_CR16 publication-title: Immunity doi: 10.1016/j.immuni.2015.07.007 – volume: 12 start-page: 137 year: 2020 ident: 531_CR37 publication-title: Allergy Asthma Immunol Res doi: 10.4168/aair.2020.12.1.137 – volume: 33 start-page: 96 year: 2015 ident: 531_CR58 publication-title: Dermatol Sin doi: 10.1016/j.dsi.2015.03.010 – volume: 107 start-page: 367 year: 2001 ident: 531_CR9 publication-title: J Allergy Clin Immunol doi: 10.1067/mai.2001.112129 – volume: 45 start-page: 24 year: 2018 ident: 531_CR60 publication-title: J Dermatol doi: 10.1111/1346-8138.14080 – ident: 531_CR25 doi: 10.1056/NEJMoa013536 – volume: 1253 start-page: 107 year: 2020 ident: 531_CR30 publication-title: Adv Exp Med Biol doi: 10.1007/978-981-15-3449-2_4 – volume: 374 start-page: 1733 year: 2016 ident: 531_CR44 publication-title: N Engl J Med doi: 10.1056/NEJMoa1514210 – volume: 134 start-page: 818 year: 2014 ident: 531_CR50 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2014.08.005 – volume: 395 start-page: 951 year: 2020 ident: 531_CR56 publication-title: Lancet doi: 10.1016/S0140-6736(19)32983-6 – volume: 15 start-page: 889 year: 2019 ident: 531_CR10 publication-title: Expert Rev Clin Immunol doi: 10.1080/1744666X.2019.1641406 – volume: 4 start-page: 1 year: 2018 ident: 531_CR27 publication-title: Nat Rev Dis Primers doi: 10.1038/s41572-018-0001-z – volume: 160 start-page: 462 year: 2018 ident: 531_CR33 publication-title: Environ Res doi: 10.1016/j.envres.2017.10.030 – volume: 172 start-page: e180315 year: 2018 ident: 531_CR38 publication-title: JAMA Pediatr doi: 10.1001/jamapediatrics.2018.0315 – volume: 155 start-page: 19 year: 2020 ident: 531_CR3 publication-title: G Ital Dermatol Venereol doi: 10.23736/S0392-0488.19.06430-7 – volume: 7 start-page: 345 year: 2019 ident: 531_CR8 publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2018.10.043 – volume: 1 start-page: 22 year: 2013 ident: 531_CR7 publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2012.11.005 – volume: 144 start-page: 1615 year: 2019 ident: 531_CR47 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2019.09.004 – volume: 57 start-page: 1 year: 2018 ident: 531_CR31 publication-title: Eur J Nutr doi: 10.1007/s00394-018-1703-4 – ident: 531_CR32 doi: 10.1111/pai.13314 – volume: 121 start-page: 313 year: 2018 ident: 531_CR48 publication-title: Ann Allergy Asthma Immunol doi: 10.1016/j.anai.2018.06.008 – volume: 163 start-page: 1333 year: 2010 ident: 531_CR29 publication-title: Br J Dermatol doi: 10.1111/j.1365-2133.2010.10068.x – volume: 235 start-page: 355 year: 2019 ident: 531_CR26 publication-title: Dermatology doi: 10.1159/000500402 – volume: 178 start-page: e19 year: 2018 ident: 531_CR52 publication-title: Br J Dermatol doi: 10.1111/bjd.15747 |
| SSID | ssj0041832 |
| Score | 2.3411665 |
| SecondaryResourceType | review_article |
| Snippet | Background
Atopic diseases, such as atopic dermatitis (AD) and food allergy (FA), have increased in prevalence in industrialized countries during the past few... Atopic diseases, such as atopic dermatitis (AD) and food allergy (FA), have increased in prevalence in industrialized countries during the past few decades and... Background Atopic diseases, such as atopic dermatitis (AD) and food allergy (FA), have increased in prevalence in industrialized countries during the past few... Abstract Background Atopic diseases, such as atopic dermatitis (AD) and food allergy (FA), have increased in prevalence in industrialized countries during the... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 30 |
| SubjectTerms | Advertising executives Allergens Allergology Anaphylaxis Antibodies Asthma Atopic dermatitis Ceramides Cytokines Dendritic cells Dermatitis Dermatologic agents Dermatology Development and progression Disease Early intervention Eczema Emergency medical care Emollients Fatty acids Filaggrin Food allergies Food allergy Formulae, receipts, prescriptions Health risk assessment Immunology Medical research Medicine Medicine & Public Health Mutation Pneumology/Respiratory System Pollutants Prevention Review Skin |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQhRAXRHmGFjASEgeImoyzfhwLouJCxQGk3oyfsBJKVrttpf57xnY2bIqAC1JO8Vhx5uGZkcffEPKyCzy0DmxtFqar0UPH2kppaxs9x-i5cd6UZhPi9FSenalPO62-Uk1YgQcujDsCZZnndiEFU1301kqHCR2ADSrIYHJohFHPNpkqe3CXFHV7RUbyo03KudJ5JabOSetqOXNDGa3_9z15xyldL5i8dmqandHJXXJnjCLpcVn9PrkR-nvk1sfxnPw--Zpxi-lyp6CRDpFigr1aOupDiVOXG2rwoasRxuky0E0Bq72iGMvSXLtVcDvS7DgMnqbWK-tvVw_Il5P3n999qMdeCrVDCzuvPUu-H2JQAE1omQxBoihkG9JBomLRSdYYIyBCAyp2nfUyWOGcC8JEbthDstcPfXhMqOAWnBA-Mtt2BrxRni2iQ0tuLLSMV6Tdsla7EWg89bv4oXPCIbku4tAoDp3FoWVFXk9zVgVm46_Ub5PEJsoEkZ1foOLoUXH0vxSnIs-TvHW5bzoZuj7GCBc9eyvxM68yRTJ1_AFnxhsLyIYEmjWjPJxRoom6-fBWp_S4RWw0xp6gABPKpiIvpuE0M5W99WG4KDQJgm8BFXlUVHD6acYEcAldRcRMOWdcmY_0y-8ZQFwoDHoZLuvNVo1_LevPXH_yP7h-QG5DNkNWt_yQ7J2vL8JTctNdos6vn2Uj_glNG0pG priority: 102 providerName: Directory of Open Access Journals – databaseName: SpringerLink dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3ba9YwFA86RXxx3q1OjSD4oGVt0i-Xx204fHGIN_YWc50fSPvxdRvsv_ckabt1XkChT80JbU7OlXPyC0IvG898bYkp9UI3JXjoUBohTGmCYxA9V9bpfNkEPzgQh4fyw3AorB-73ceSZLLUSa0F2-5j3hRrjpD-RskpxVV0DdydiOr48dPX0f42UUjH4zG_nTdzQQmp_1d7fMEhXW6WvFQxTY5of_P_lnAb3RoCT7yTJeUOuuLbu-jG-6G0fg99S1DHeHmhBxJ3AUNOvlpa7HwObZc91vDg1YD8dOpxn_FtzzCEvzi1e2Wojzg7dJ3D8baW9dHZffRl_-3nvXflcP1CaUEpj0tHY7hAgpeEVL6mwnsBuydqH2uPkgYraKU1J4FURIamMU54w621nuvANH2ANtqu9Y8Q5swQy7kL1NSNJk5LRxfBgvJXhtSUFaged0TZAZs8XpHxQ6UcRTCVWaeAdSqxTokCvZ7mrDIyx1-pd-NGT5QRVTu96NZHalBSRaShjpmF4FQ2wRkjLJMQ5BgvvfBaF-h5FBOVj6hOtkHtQFAMwUAt4DOvEkW0DrAAq4dDDsCGiLM1o9yaUYJW2_nwKIpqsCq9gnCVSAI5aFWgF9NwnBk75VrfnWSaiNq3IAV6mCV3WjSlnDBBmgLxmUzPuDIfaZffE-Y4lxAnU_itN6Nkn__Wn7n--N_In6CbJCkHLWu2hTaO1yf-KbpuT0G618-Slv8EQUBNVw priority: 102 providerName: Springer Nature |
| Title | Early intervention of atopic dermatitis as a preventive strategy for progression of food allergy |
| URI | https://link.springer.com/article/10.1186/s13223-021-00531-8 https://www.ncbi.nlm.nih.gov/pubmed/33726824 https://www.proquest.com/docview/2502928620 https://www.proquest.com/docview/2502211952 https://pubmed.ncbi.nlm.nih.gov/PMC7962338 https://doaj.org/article/29b3d6b587394fdbb8c69022be9e8eaa |
| Volume | 17 |
| WOSCitedRecordID | wos000629581000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: Open Access: BioMedCentral Open Access Titles customDbUrl: eissn: 1710-1492 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0041832 issn: 1710-1492 databaseCode: RBZ dateStart: 20040101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Open Access Full Text customDbUrl: eissn: 1710-1492 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0041832 issn: 1710-1492 databaseCode: DOA dateStart: 20050101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVPQU databaseName: Health & Medical Collection (Proquest) customDbUrl: eissn: 1710-1492 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0041832 issn: 1710-1492 databaseCode: 7X7 dateStart: 20150101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Healthcare Administration Database (Proquest) customDbUrl: eissn: 1710-1492 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0041832 issn: 1710-1492 databaseCode: M0T dateStart: 20150101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthmanagement providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1710-1492 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0041832 issn: 1710-1492 databaseCode: BENPR dateStart: 20150101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Publicly Available Content customDbUrl: eissn: 1710-1492 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0041832 issn: 1710-1492 databaseCode: PIMPY dateStart: 20150101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary Collection customDbUrl: eissn: 1710-1492 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0041832 issn: 1710-1492 databaseCode: RSV dateStart: 20050301 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3Nb9MwFLdYhxAXvgeBMYyExAGiJXZqOye0oU1waFWNgcrJ-HNUQk1pt0n773l2nG4ZYhekKFLiZyX2-_Cz_fx7CL2pHHOlITpXQ1XlMEL7XAuhc-0tA--5MFa1ySb4eCym03qSFtxWKayys4nRUNvGhDXyXRiqSU3A_y4-LH7nIWtU2F1NKTQ20GZAKqsGaHP_YDw56mxxFQQ2HokMMQiVqLpjM4LtrsI8LOxhwnQ6SGIuekNTRPD_205fGaiuB1Fe20mNA9Th_f9t2gN0L7mmeK-VpYfolps_QndGafP9MfoRwZDx7EqUJG48hln7Ymawda3zO1thBRdeJGyoc4dXLQLuBQYHGceAsBYMJNT2TWNxyOeyPLl4gr4eHhx__JSnBA25AbU9zS0NDgXxriakcCUVzgngryhd2J2sqTeCFkpx4gm00FeVtsJpboxxXHmm6BYazJu5e4YwZ5oYzq2nuqwUsaq2dOgNmIdCk5KyDJUdb6RJ6OUhicYvGWcxgsmWnxL4KSM_pcjQu3WdRYvdcSP1fmD5mjLgbscXzfJEJjWWpNbUMj0UnNaVt1oLw2pwg7SrnXBKZehVEBjZHmJdWw-5B24zuAulgM-8jRTBfkADjErHIKAbAhJXj3K7Rwl6b_rFnTTJZHdW8lKUMvR6XRxqhli6uWvOWpqgLUOSoaetDK8bTSknTJAqQ7wn3b1e6ZfMZz8jKjmvwZOm8FvvOz24_K1_9_rzm1vxAt0lUUNpXrJtNDhdnrmX6LY5B2le7qANPuXxLnaS5u_ERRW4j4pjeDf5PJp8h6ejL9_-AE58YQI |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9NAFB6VgoAL-2IodJBAHIpVe8axxweEylK1ahNxCFJv01nbSFUckrQof4rfyHtjO62L6K0HpJwyb-KZyfc2z1sIeZu53KWG6Vj1VBaDhvaxFkLH2tscrOfEWFU3mygGA3FwUH5fIb_bXBgMq2xlYhDUtjL4jnwTVDUrGdjfyafJzxi7RuHtattCo4bFnlv8Apdt9nH3K_y_7xjb_jb8shM3XQViA1ibx5ajFmTelYwlLuXCOQGLEqnDK7WSeyN4olTBPIMn-izTVjhdGGNcoXyuOPzuDXIT6-phCGE_GbaSP0P2CAmYGPGQiaxN0hH55gy9PrwxBecdcR-LjiIM_QL-1goX1OLlkM1L97ZBHW7f_98O8gG51xjedKvmlIdkxY0fkdv9JrTgMTkMpZ7p6EIMKK08VfNqMjLUutq0H82ogg-dNJWvzhyd1fV9FxTMfxrC3epSJzjbV5Wl2K1merR4Qn5cy_6ektVxNXbPCS1yzUxRWM91milmVWl5zxsQfolmKc8jkrZYkKapzY4tQk5k8NFELmv8SMCPDPiRIiIbyzmTujLJldSfEWJLSqwqHr6opkeyEVKSlZrbXPdEwcvMW62FyUsw8rQrnXBKRWQdASrrFN2lbJRb4BSAMZQKeMz7QIHSETZgVJPkAceAdcY6lGsdSpBqpjvcolc2UnUmz6EbkTfLYZyJkYJjV53WNFi1sMci8qzmmeWmOS9YLlgWkaLDTZ1T6Y6MR8eh5npRgp_AYVkfWr47X9a_T_3F1btYJ3d2hv19ub872HtJ7rIgHXic5mtkdT49da_ILXMGyJ6-DnKGksPr5sc_Z6W10w |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Zb9QwELagoIoX7iNQqJGQeICoiZ318ViOCgSsKnGob8ZnWQklq91tpf57xnaybMohIaQ8xWMlHs-MZzQznxF60njma0tMqSe6KeGEDqURwpQmOAbec2WdzpdN8OlUHB3Jw40u_lTtPqQkc09DRGlqV3tzF7KKC7a3jDFUzD9CKBylqBQX0aUmXhoU4_WPXwZb3ESBHVplfjtvdBwl1P5fbfPG4XS-cPJc9jQdSgfX_n8519HV3iHF-1mCbqALvr2Jtj_0Kfdb6GuCQMazjdpI3AUMsfp8ZrHz2eWdLbGGB897RKhTj5cZ9_YMg1uMUxlYhgCJs0PXORxvcVkcn91Gnw9ef3r5puyvZSgtKOuqdDS6ESR4SUjlayq8F7CrovYxJylpsIJWWnMSSEVkaBrjhDfcWuu5DkzTO2ir7Vp_D2HODLGcu0BN3WjitHR0EiwYhcqQmrIC1cPuKNtjlserM76rFLsIpjLrFLBOJdYpUaBn6znzjNjxV-oXcdPXlBFtO73oFseqV15FpKGOmYngVDbBGSMsk-D8GC-98FoXaDeKjMqtq2ubofbBWQYnoRbwmaeJIloNWIDVffMDsCHib40od0aUoO12PDyIpeqtzVKBG0skgdi0KtDj9XCcGSvoWt-dZJqI5jchBbqbpXi9aEo5YYI0BeIj-R5xZTzSzr4lLHIuwX-m8FvPByn_-Vt_5vr9fyPfRduHrw7U-7fTdw_QFZL0hJY120Fbq8WJf4gu21MQ9MWjpPw_ANPLWR8 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Early+intervention+of+atopic+dermatitis+as+a+preventive+strategy+for+progression+of+food+allergy&rft.jtitle=Allergy%2C+asthma%2C+and+clinical+immunology&rft.au=Sweeney%2C+Alyssa&rft.au=Sampath%2C+Vanitha&rft.au=Nadeau%2C+Kari+C&rft.date=2021-03-16&rft.issn=1710-1484&rft.volume=17&rft.issue=1&rft.spage=30&rft_id=info:doi/10.1186%2Fs13223-021-00531-8&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1710-1492&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1710-1492&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1710-1492&client=summon |